Metastatic castration-resistant prostate cancer (mCRPC) Market Outline:
The 9MMMetastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
This form of cancer refers, when prostate cancer advanced to an stage and spreads beyond the prostate gland to other parts of the body. With Metastatic Castration-Resistant Prostate Cancer (mCRPC), hormone therapy no longer stops cancer growth. Common symptoms are Trouble urinating, blood in urine, Weight loss, Shortness of breath, Bone pain among others.
Report has covered granular-level analysis in each mapped market
Metastatic castration-resistant prostate cancer (mCRPC), Disease Burden Analysis: (Result shown here is refelecting from studies metanalysis, and CSP Analytics Solutions Analysis)
The prevalence of mCRPC estimated approximately 1.2% to 2.1% of prostate cancer cases
Around 25% of patients with mCRPC have gene alterations in the tumor associated with homologous recombination repair
Annually there are approximately 1,140,042 new cases of prostate cancer (PC) diagnosed across the globe
Prostate Cancer Prevalent Pool XXXX (Absolute value)
Non metastatic (Absolute value)
T0/TX (Absolute value)
T1/T2 (Absolute value)
T3/T4 (Absolute value)
Metastatic (Absolute value)
mHSPC (Absolute value)
mCRPC (Absolute value)
Treatment Landscape:
Metastatic castration-resistant prostate cancer (mCRPC) market is struggling to get an effective treatment
Advancement in biomarkers is essential for developing a targeted therapy
Chemotherapy is currently the mainstay of systemic therapy for patients
The developement of Bone-targeted Agents, PARP Inhibitors, Radiopharmaceuticals, expected to change the therapeutic landscape of Metastatic castration-resistant prostate cancer (mCRPC)
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each therapy type:
Report has examined the how many and what type of cases refer to which type of therapy based on experts opinion analysis.
Report also provided promising therapy assessment including drugs, existing therapies and upcoming therapy
Novel drug target assessmment. For instance. Sipuleucel-T (S-T), a therapeutic cancer vaccine, is an autologous cellular immunotherapy that has been found to lower the risk of mortality in mCRPC patients
Expected launch of key pipeline assets
Promising molecules advantages offer over existing therapy
Untreated Prevalent Pool of Metastatic castration-resistant prostate cancer (mCRPC)
Significant development in biomarkers
Conducive reimbursement, pricing strategies, and market access ecosystems
Huge medical unmet need
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Lack of timely diagnosis
Research gap
Cost of therapy
Treatment compliance and adherence
Recent Developments:
March, 2022: FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
5-Europe Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
Janssen Biotech (a subsidiary of Johnson & Johnson)
Astellas Pharma
Bristol Myers Squibb (BMS)
Pfizer
AstraZeneca
Sanofi Genzyme
Clovis Oncology
Exelixis
Merck & Co. (MSD outside the United States and Canada)
Bayer
Novartis
Seattle Genetics
Others
Reason to buy this report:
Fostering Understanding on Metastatic castration-resistant prostate cancer (mCRPC) Drug Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
